

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder

Christina Shaw¹, William Gibson²

¹Division of Geriatric Medicine, University of British Columbia, Vancouver, British Columbia, Canada; ²Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada

Correspondence: William Gibson, Division of Geriatric Medicine, University of Alberta, 1-198 Clinical Sciences Building, 11350 83 Ave NW, Edmonton, Alberta, T6E 2K4, Canada, Tel +1 780 248 1969, Fax +1 780 492 2874, Email wgibson@ualberta.ca

Abstract: Lower urinary tract symptoms (LUTS), including urgency, frequency, and urgency incontinence, are highly prevalent in the general population and increase in prevalence with increasing age. All LUTS, but notable urgency and urgency incontinence, are associated with negative impact on quality-of-life (QoL), with multiple aspects of QoL affected. Urgency and urgency incontinence are most commonly caused by overactive bladder (OAB), the clinical syndrome of urinary urgency, usually accompanied by increased daytime frequency and/or nocturia in the absence of infection or other obvious etiology, which may be treated with conservative and lifestyle interventions, bladder antimuscarinic drugs, and, more recently, by mirabegron, a β_3 agonist. This narrative review describes the impact of OAB on QoL, quantifies this impact, and outlines the evidence for the use of mirabegron in the treatment of, and improvement in QoL in, people with OAB.

Keywords: lower urinary tract symptoms, incontinence, quality-of-life, health-related quality-of-life, mirabegron

Introduction

It is well recognized that lower urinary tract symptoms (LUTS) including urgency, frequency, and urinary incontinence (UI) are highly prevalent in the general population and increase in prevalence in association with increasing age.^{1,2} Urgency, defined by the International Continence Society as the complaint of a sudden, compelling desire to void which is difficult to defer,³ is a particularly bothersome symptom, even in the absence of incontinence.⁴ The syndrome of urinary urgency, usually accompanied by increased daytime frequency and/or nocturia in the absence of infection or other obvious etiology, is termed overactive bladder (OAB) and may be associated with UI (termed OAB-wet) or without (OAB-dry).⁵ is a common cause of incontinence in both men and women and is associated with a significant negative impact on quality-of-life (QoL).⁶ Beliefs that LUTS and UI are a normal part of aging, as well as the stigma associated with them lead patients to not seek care.⁷

Multiple guidelines for the treatment of LUTS and UI in older adults stress the importance of conservative management, including the treatment of constipation, fluid intake normalization, treatment of underlying conditions and polypharmacy, and bladder training prior to pharmacotherapy,^{8,9} with bladder antimuscarinics and beta-3 agonists being available options.

While anticholinergic agents for the treatment of OAB have been available for many years,¹⁰ concerns around anticholinergic side-effects and the tolerability of these agents led to the beta-3 agonist mirabegron being developed in the mid-2000s, and it was first licenced in the early 2010s.¹¹

This review will examine the evidence on mirabegron's effect on QoL in patients with OAB, with and without associated urgency incontinence.

Overactive Bladder Epidemiology

As with most LUTS, prevalence rates of OAB are difficult to estimate due to few population-based studies. In those that have been done significant heterogeneity exists regarding definitions used, inclusion and exclusion criteria, and how symptoms are

assessed/measured. Prevalence estimates range between 2% and 53%, with most studies estimating between 10% and 20%.¹² The EPIC study found the prevalence of OAB was 11.8% using data from five European countries.¹ In EpiLUTS, 35.7% of women and 22.4% of men experienced urgency.¹³ A recent epidemiology study in Canada found that OAB was experienced by 12.3% of respondents, in a nationally representative adult sample.¹⁴ Urgency UI was endorsed by 5.3% of respondents. Prevalence estimates change when the degree of bother is reported.^{13,15} In the EPIC study, of those with OAB nearly half endorsed UI, and there was an increased level of bother seen in the incontinent group.¹

Pathophysiology

The pathophysiology of the symptom complex of OAB is not yet well understood. While once thought to be synonymous with detrusor overactivity (DO), there is only a moderate correlation between OAB symptoms and the presence of DO on multichannel subtracted cystometry.¹⁶ In older adults, LUTS including OAB and UI are most often multifactorial, and the role of abnormalities in the neural control of the bladder cannot be understated.¹⁷ Functional brain imaging, including functional magnetic resonance imaging (fMRI) and single-photon emission computed tomography (PET), have demonstrated periaqueductal gray matter, pons, and the ventral and dorsal portions of the pontine tegmentum are activated during the filling phase of voiding and may be involved in suppressing the voiding reflex. Damage to these areas, such as the development of white matter hyperintensities, may impair the ability to suppress the voiding reflex.¹⁸ A recent study in Japanese older adults showed that participants with OAB showed a higher volume of WMH than those without OAB.¹⁹ OAB in older adults is, at least in part, a “brain disease”.²⁰

Quality-of-Life

LUTS are highly stigmatizing symptoms²¹ which impact an individual's QoL in numerous interacting ways. QoL data are most robust with UI, studies consistently showing UI to be associated with a lower QoL and poor self rated health.^{22,23} A systematic review in 2010 including both UI and OAB demonstrated that OAB-dry impairs QoL.²⁴ However, QoL has been shown to be worse in those with UI.²⁵ When further categorizing UI, urgency UI (as associated with OAB-wet) is often seen to be the most impairing,²⁶ along with mixed UI, though in mixed it is the urgency component that has the biggest effect.²⁷ Data have suggested that it is the symptom severity, rather than type of incontinence that is most associated with impaired QoL.^{25,28} Similarly, the degree of impact of OAB appears to be related to both the presence of urgency UI and the overall severity of the condition.²⁴ This opens the door for action, for if lifestyle or pharmacological interventions can reduce the severity of symptoms, even without cure, it may significantly improve QoL.

While UI may be considered the most bothersome symptom of OAB, other LUTS such as urgency also impact QoL. A study of Spanish men found that the frequency of urgency episodes was inversely proportional to health-related quality-of-life (HRQoL).²⁹ Urgency is the LUTS with the greatest population level burden, at the individual level the LUTS with the greatest bother is urgency UI.⁴ A nested study within the EPIC cohort demonstrated that men and women with OAB equally reported symptom bother; more bother was associated with urgency than stress incontinence.³⁰

UI has consistently been associated with shame,³¹ depressive symptoms,³² poor self-rated health,³³ falls,³⁴ and high expense.³⁵ Similarly, OAB has been found to be associated with feelings of depression and stress, worry and shame, and feeling uncomfortable in social situations.³⁶ While it is well recognized that people with LUTS will often not seek healthcare,³⁷ the level of bother of LUTS impacts the likelihood of health care seeking, with patients with high bother being more likely to initiate a conversation with a healthcare provider, even with the same frequency and severity of symptoms.³⁰

A population-based study of OAB and urgency UI in the US, UK, and Sweden of adults aged 40–65 demonstrated decreased work productivity in men and women with OAB, most pronounced among those with UI.³⁸ Patients with OAB-wet may worry about interrupting meetings and often consider their urinary symptoms in decisions about work hours and location. Urgency accompanied by a fear of leaking and perceived daytime frequency were most strongly associated with work productivity impairment in both men and women. Associations were also seen with storage, voiding, and micturition symptoms. EPIC found similar findings, with the addition that men with OAB were more likely to be retired than those without OAB, and also showed that those with OAB demonstrated less work productivity and sexual satisfaction, higher rates of depressive symptoms and erectile dysfunction, and lower levels of overall health.³⁰

Care partners of those experiencing LUTS are also affected by their partner's symptoms. Providing continence care is considered burdensome, requiring significant time and energy expenditure. In addition to physical burden, LUTS and UI affect psychological well-being by causing worry, sleep deprivation, and burnout.^{39–41} UI is an independent predictor of institutionalization in those with dementia, as it is often the symptom for which caregivers are no longer able to provide care at home.^{42–44}

QoL Tools

Numerous validated tools have been developed to assess and quantify the impact of LUTS on QoL. For both sexes, the International Consultation on Incontinence Questionnaire – Quality of Life (ICIQ LUTS-QoL) is a validated questionnaire assessing the impact of a variety of LUTS on QoL.^{45–47} It is a 22-item questionnaire with possible scores of 19–76, with higher scores indicating increased impact on QoL. Many domains are assessed, including household tasks, relationships, activity, and mental health. Bother is also assessed for each included domain.

Several scales have been validated specifically for OAB: the overactive bladder questionnaire (OAB-q),⁴⁸ the patient perception of bladder condition (PPBC),⁴⁹ and the treatment satisfaction visual analog scale (TS-VAS).⁵⁰ These tools also assess symptom bother in OAB, which is an important consideration for how OAB is impacting QoL. The ICIQ-Cog was developed to assess how LUTS impact QoL in cognitively impaired individuals.⁵¹ The minimally important difference (MID), the smallest change in response outcome that is perceived as meaningful by the patient, has been estimated as 10 points for all OAB-q subscales.⁵²

Mirabegron

Safety, Efficacy, Tolerability

Mirabegron was the first beta-3 adrenoceptor agonist to enter the market. It was approved for use initially in the United States and the European Union. Mirabegron was developed to target the beta-3 adrenoceptors that make up the majority of beta-adrenoceptors in the detrusor muscle and urothelium.⁵³ Available dosage forms are 25 mg, 50 mg, and 100 mg tablets. Metabolism occurs in the liver with involvement of the cytochrome P450 system. Excretion is via urine and feces.

Phase II and III randomized controlled trials (RCTs) (BLOSSOM, DRAGON, SCORPIO, ARIES, CAPRICORN, TAURUS) demonstrated mirabegron to be superior to placebo in a number of micturitions and incontinence episodes in 24 hours.^{54–59} Pooled analysis from three trials also demonstrates a statistically significant dry rate as well as a decrease in incontinence episodes by 50%.⁶⁰ Participants across all studies were adult men and women over 18 years with OAB symptoms for over 3 months. An assessment of pooled data showed improvement in incontinence episodes and micturitions per day in older adults over 65 years.⁶¹ Evidence of benefit was seen early and was maintained throughout treatment. A placebo-controlled trial of older adults over age 65 (PILLAR) also demonstrated improvement in the number of micturition and incontinence episodes per day.⁶²

Discussions around the safety of mirabegron have predominantly focused on cardiovascular safety, given the presence of beta-3 adrenoceptors in cardiac and vascular tissue. In one healthy volunteer study, supratherapeutic doses of mirabegron was associated with QTc prolongation in women, and also with a dose-dependent increase in heart rate (6.7, 11, and 17 bpm for the 50, 100, and 200 mg dose groups, respectively).⁶³ These cardiovascular effects have not been seen in any other trial. Pulse increases in the clinical trials were more modest (1–5 bpm, depending on dosage and time of day). Blood pressure effects were similarly modest in the clinical studies, with only a 1 mmHg increase in systolic or diastolic blood pressure. A Canadian population-based cohort study did not find increased incidence of arrhythmia, tachycardia, myocardial infarction, or stroke within 1 year from initiation when compared to other OAB drugs.⁶⁴ Few other adverse effects have been reported. Pooled safety data from three trials looked at post-void residuals (PVR) and found unremarkable change in mirabegron 50 mg and 100 mg doses, as well as tolterodine and placebo groups, and the number of patients with PVR over 150 mL was lower in both mirabegron groups.⁶⁰ In that population, the number of patients who experienced acute urinary retention was less than 1%, and was lower than the tolterodine or placebo groups.

The most common adverse effects (AE) reported in the RCTs were hypertension, nasopharyngitis, urinary tract infection, headache, pruritis, constipation, diarrhea, and dry mouth.^{42–47} Across all studies, the majority of AE were mild

or moderate, and discontinuation rates were low. AE were similar between anticholinergic (tolterodine), mirabegron, and placebo groups, except dry mouth and pruritis which were 5-times higher in the anticholinergic groups. In PILLAR, there was a slightly higher incidence of AE in the over 75 years age group compared to the less than 75 years age group, but no meaningful differences in HR or BP were seen in either group.⁶² A meta-analysis of trials comparing mirabegron to solifenacin demonstrated similar efficacy with greater tolerability in the mirabegron group due to the lack of anticholinergic side-effects.⁶⁵

Quality-of-Life

As with many trials of medications for OAB, the primary endpoints of trials of mirabegron were usually objective and easily measured parameters such as voids per day or occurrences of incontinence. Several trials of mirabegron have used patient-reported measures or HRQoL as secondary endpoints.^{55–58} These phase II and III trials used OAB-specific QoL scales. In those studies that utilized the OAB-q, all domains exceeded the MID, except for the OAB-q Social Interaction domain in three trials.^{57–59} Using the PBC, in two trials, there was a minimally important difference in QoL scales between mirabegron and placebo.^{56,57} Another trial also demonstrated this but the result was not statistically significant.⁵⁷ DRAGON used ICIQ-OABqol and demonstrated improved QoL scores with increased dosages.⁵⁵

A large European observational study (BELIEVE) demonstrated improved symptom bother and HR-QoL scores at 2–4 and 10–12 month follow-ups.⁶⁶ More patients achieved MID at 10–12 months than 2–4 months (symptom bother 71.2% vs 43.8%, HRQoL 63.1% vs 37.2%), with a greater improvement in women than men. At 10–12 months, 53.8% of patients were still receiving mirabegron, the remainder having discontinued treatment entirely or switched to a different agent. However, another observational study in the UK demonstrated only a 38% 12-month persistence rate.⁶⁷ Secondary analysis of BELIEVE participants only age 65 and over demonstrated that older adults' symptom bother scores improved similarly to younger patients, and proportions of older patients with improvement were similar to younger patients.⁶⁸

Few studies have assessed the effect of mirabegron on caregivers of those with OAB. One prospective, non-randomized study⁶⁹ of 186 caregivers of older women with urgency or mixed incontinence in Greece found that the caregivers of those women treated with mirabegron, compared to conservative management, had significant reductions in the Zarit Burden Scale after 3 months of treatment.

Conclusion

OAB, a symptom complex characterized by urgency, nocturia, and sometimes urgency UI, is a condition that has significant and deleterious impact on QoL, as the symptoms are often associated with significant bother. In younger people, it has significant implications for work and employment, and in older people it also affects the QoL of caregivers and increases the likelihood of institutionalization. Mirabegron has been shown to be safe, tolerable, and efficacious in patients with OAB. It may be more tolerable to patients than the available anticholinergic medications due to a lower burden of anticholinergic side-effects. Use of mirabegron has been associated with improved QoL scores of patients in randomized-controlled trials and real-world observational studies. Decreased burden has also been demonstrated in caregivers of patients on mirabegron for OAB. Patient-reported outcome measures and measures of quality-of-life impacts should be included and prioritized in future research into treatments for OAB.

Disclosure

Dr William Gibson reports grants from Pfizer Canada, outside the submitted work. The authors report no other conflicts of interest in this work.

References

1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol*. 2006;50(6):1306–14; discussion 1314–5. doi:10.1016/j.eururo.2006.09.019
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int*. 2001;87(9):760–766. doi:10.1046/j.1464-410x.2001.02228.x
3. D'Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. *Neurourol Urodyn*. 2019;38(2):433–477. doi:10.1002/nau.23897

4. Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. *Eur Urol*. 2014;65(6):1211–1217. doi:10.1016/j.eururo.2014.01.019
5. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn*. 2010;29(1):4–20. doi:10.1002/nau.20798
6. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. *Am J Manag Care*. 2000;6(11 Suppl):S580–90.
7. Teunissen D, van Weel C, Lagro-Janssen T. Urinary incontinence in older people living in the community: examining help-seeking behaviour. *Br J Gen Pract*. 2005;55(519):776–782.
8. NICE UK. *Urinary Incontinence: The Management of Urinary Incontinence in Women (CG40)*. NICE UK; 2006.
9. Wagg A, Gibson W, Ostaszewicz J, et al. Urinary incontinence in frail elderly persons: report from the 5th International Consultation on Incontinence. *Neurourol Urodyn*. 2015;34(5):398–406. doi:10.1002/nau.22602
10. Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. *Ther Adv Urol*. 2018;10(12):411–419. doi:10.1177/1756287218801282
11. Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. *Expert Opin Drug Discov*. 2014;9(4):433–448. doi:10.1517/17460441.2014.892923
12. Paul Abrams LC, Wagg A, Wein A. *Incontinence: 6th International Consultation on Incontinence*. Tokyo: ICUD ICS; 2017.
13. Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. *BJU Int*. 2009;103(Suppl 3):4–11. doi:10.1111/j.1464-410X.2009.08371.x
14. Shaw C, Cahill J, Wagg A. The current state of continence in Canada: a population representative epidemiological survey. *Can J Urol*. 2020;27(4):10300–10305.
15. Vaughan CP, Johnson TM, Ala-Lipasti MA, et al. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. *Eur Urol*. 2011;59(4):629–636. doi:10.1016/j.eururo.2011.01.031
16. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? *J Urol*. 2006;175(1):191–4; discussion 194–5. doi:10.1016/S0022-5347(05)00067-4
17. Shaw C, Wagg A. Overactive bladder in frail older adults. *Drugs Aging*. 2020;37(8):559–565. doi:10.1007/s40266-020-00777-8
18. Smith PP, Kuchel GA, Griffiths D. Functional brain imaging and the neural basis for voiding dysfunction in older adults. *Clin Geriatr Med*. 2015;31(4):549–565. doi:10.1016/j.cger.2015.06.010
19. Komiya H, Umegaki H, Ogama N, et al. Relationships between overactive bladder and cerebral white matter hyperintensity in outpatients at a memory clinic. *Geriatr Gerontol Int*. 2021;21(11):996–1002. doi:10.1111/ggi.14279
20. Sakakibara R, Panicker J, Fowler CJ, et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. *Int J Urol*. 2014;21(1):33–38. doi:10.1111/iju.12288
21. Elstad EA, Taubenberger SP, Botelho EM, et al. Beyond incontinence: the stigma of other urinary symptoms. *J Adv Nurs*. 2010;66(11):2460–2470. doi:10.1111/j.1365-2648.2010.05422.x
22. Stewart WF, Van Rooyen J, Cundiff G, et al. Prevalence and burden of overactive bladder in the United States. *World J Urol*. 2003;20(6):327–336. doi:10.1007/s00345-002-0301-4
23. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. *Value Health*. 2004;7(4):455–463. doi:10.1111/j.1524-4733.2004.74008.x
24. Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. *Urology*. 2010;75(3):491–500. doi:10.1016/j.urology.2009.07.1325
25. Chiaffarino F, Parazzini F, Lavezzari M, et al. Impact of urinary incontinence and overactive bladder on quality of life. *Eur Urol*. 2003;43(5):535–538. doi:10.1016/S0302-2838(03)00097-6
26. Hagglund D, Walker-Engström ML, Larsson G, et al. Quality of life and seeking help in women with urinary incontinence. *Acta Obstet Gynecol Scand*. 2001;80(11):1051–1055.
27. Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. *BJU Int*. 2003;92(7):731–735. doi:10.1046/j.1464-410X.2003.04463.x
28. Barentsen JA, Visser E, Hofstetter H, et al. Severity, not type, is the main predictor of decreased quality of life in elderly women with urinary incontinence: a population-based study as part of a randomized controlled trial in primary care. *Health Qual Life Outcomes*. 2012;10:153. doi:10.1186/1477-7525-10-153
29. Cambroner Santos J, Errando Smet C. Prevalence of storage lower urinary tract symptoms in male patients attending Spanish urology office. Urinary urgency as predictor of quality of life. *Actas Urol Esp*. 2016;40(10):621–627. doi:10.1016/j.acuro.2016.04.012
30. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU Int*. 2008;101(11):1388–1395. doi:10.1111/j.1464-410X.2008.07601.x
31. Farage MA, Miller KW, Berardesca E, et al. Psychosocial and societal burden of incontinence in the aged population: a review. *Arch Gynecol Obstet*. 2008;277(4):285–290. doi:10.1007/s00404-007-0505-3
32. Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. *J Am Geriatr Soc*. 2000;48(4):413–416. doi:10.1111/j.1532-5415.2000.tb04699.x
33. Johnson TM, Kincade JE, Bernard SL, et al. The association of urinary incontinence with poor self-rated health. *J Am Geriatr Soc*. 1998;46(6):693–699. doi:10.1111/j.1532-5415.1998.tb03802.x
34. Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. *Aust J Physiother*. 2009;55(2):89–95. doi:10.1016/S0004-9514(09)70038-8
35. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. *Obstet Gynecol*. 2001;98(3):398–406. doi:10.1016/s0029-7844(01)01464-8
36. Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. *BJU Int*. 2006;97(1):96–100. doi:10.1111/j.1464-410X.2005.05889.x
37. Irwin DE, Milsom I, Kopp Z, et al. Symptom bother and health care-seeking behavior among individuals with overactive bladder. *Eur Urol*. 2008;53(5):1029–1037. doi:10.1016/j.eururo.2008.01.027

38. Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. *Am J Manag Care*. 2009;15(4 Suppl):S98–S107.
39. Cassells C, Watt E. The impact of incontinence on older spousal caregivers. *J Adv Nurs*. 2003;42(6):607–616. doi:10.1046/j.1365-2648.2003.02664.x
40. Di Rosa M, Lamura G. The impact of incontinence management on informal caregivers' quality of life. *Aging Clin Exp Res*. 2016;28(1):89–97. doi:10.1007/s40520-015-0367-7
41. Santini S, Andersson G, Lamura G. Impact of incontinence on the quality of life of caregivers of older persons with incontinence: a qualitative study in four European countries. *Arch Gerontol Geriatr*. 2016;63:92–101. doi:10.1016/j.archger.2015.10.013
42. Maxwell CJ, Soo A, Hogan DB, et al. Predictors of nursing home placement from assisted living settings in Canada. *Can J Aging*. 2013;32(4):333–348. doi:10.1017/S0714980813000469
43. Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. *Value Health*. 2006;9(4):272–274. doi:10.1111/j.1524-4733.2006.00109.x
44. Nuotio M, Tammela TLJ, Luukkaala T, et al. Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence. *J Gerontol A Biol Sci Med Sci*. 2003;58(8):756–762. doi:10.1093/gerona/58.8.M756
45. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. *Neurourol Urodyn*. 2004;23(4):322–330. doi:10.1002/nau.20041
46. Abrams P, Avery K, Gardener N, et al. The international consultation on incontinence modular questionnaire. *J Urol*. 2006;175(3 Pt 1):1063–6; discussion 1066. doi:10.1016/S0022-5347(05)00348-4
47. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. *Br J Obstet Gynaecol*. 1997;104(12):1374–1379. doi:10.1111/j.1471-0528.1997.tb11006.x
48. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. *Qual Life Res*. 2002;11(6):563–574. doi:10.1023/A:1016370925601
49. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. *Eur Urol*. 2006;49(6):1079–1086. doi:10.1016/j.eururo.2006.01.007
50. Abdel-Fattah M, Ramsay I, Barrington JW. A simple visual analogue scale to assess the quality of life in women with urinary incontinence. *Eur J Obstet Gynecol Reprod Biol*. 2007;133(1):86–89. doi:10.1016/j.ejogrb.2006.04.034
51. Volz-Sidiropoulou E, Rings T, Wagg AS, et al. Development and initial psychometric properties of the 'ICIQ-Cog': a new assessment tool to measure the disease-related impact and care effort associated with incontinence in cognitively impaired adults. *BJU Int*. 2018;122(2):309–316. doi:10.1111/bju.14186
52. Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. *J Urol*. 2006;176(2):627–32; discussion 632. doi:10.1016/j.juro.2006.03.088
53. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. *Neurourol Urodyn*. 2014;33(1):17–30. doi:10.1002/nau.22505
54. Chapple CR, Amarencio G, López Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. *Neurourol Urodyn*. 2013;32(8):1116–1122. doi:10.1002/nau.22373
55. Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. *Int Urogynecol J*. 2013;24(9):1447–1458. doi:10.1007/s00192-013-2042-x
56. Khullar V, Amarencio G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian Phase 3 trial. *Eur Urol*. 2013;63(2):283–295. doi:10.1016/j.eururo.2012.10.016
57. Nitti VW, Auerbach S, Martin N, et al. Results of a randomized Phase III trial of mirabegron in patients with overactive bladder. *J Urol*. 2013;189(4):1388–1395. doi:10.1016/j.juro.2012.10.017
58. Herschorn S, Barkin J, Castro-Diaz D, et al. A Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. *Urology*. 2013;82(2):313–320. doi:10.1016/j.urology.2013.02.077
59. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. *Eur Urol*. 2013;63(2):296–305. doi:10.1016/j.eururo.2012.10.048
60. Nitti VW, Khullar V, Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. *Int J Clin Pract*. 2013;67(7):619–632. doi:10.1111/ijcp.12194
61. Khullar V, Cambronero J, Angulo J, et al. Age-related efficacy of the selective B3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged ≥ 65 years. Proceedings of the 42nd annual meeting of the International Continence Society; 2012:Abstract 331.
62. Wagg A, Staskin D, Engel E, et al. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a Phase IV, double-blind, randomised, placebo-controlled study (PILLAR). *Eur Urol*. 2020;77(2):211–220. doi:10.1016/j.eururo.2019.10.002
63. Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. *Clin Pharmacol Ther*. 2012;92(6):696–706. doi:10.1038/clpt.2012.181
64. Tadrus M, Matta R, Greaves S, et al. Association of Mirabegron with the risk of arrhythmia in adult patients 66 years or older—a population-based cohort study. *JAMA Intern Med*. 2019;179(10):1436–1439. doi:10.1001/jamainternmed.2019.2011
65. Wang J, Zhou Z, Cui Y, et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. *Neurourol Urodyn*. 2019;38(1):22–30. doi:10.1002/nau.23863
66. Freeman R, Foley S, Rosa Arias J, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. *Curr Med Res Opin*. 2018;34(5):785–793. doi:10.1080/03007995.2017.1419170
67. Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. *Eur Urol*. 2017;72(3):389–399. doi:10.1016/j.eururo.2017.01.037
68. Foley S, Choudhury N, Huang M, et al. Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: secondary analysis of BELIEVE. *Int J Urol*. 2019;26(9):890–896. doi:10.1111/iju.14050
69. Zachariou A, Filiponi M, Katsas A, et al. Mirabegron alleviates the degree of burden experienced by caregivers of older females with mixed or urge incontinence: a prospective study. *Clin Interv Aging*. 2021;16:291–299. doi:10.2147/CIA.S283737

Therapeutics and Clinical Risk Management

Dovepress

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>